Egetis Therapeutics AB (publ) (FRA:P0F)

Germany flag Germany · Delayed Price · Currency is EUR
0.401
-0.023 (-5.43%)
At close: Dec 4, 2025
-12.55%
Market Cap 171.44M
Revenue (ttm) 5.01M
Net Income (ttm) -30.15M
Shares Out n/a
EPS (ttm) -0.08
PE Ratio n/a
Forward PE 17.57
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.401
Previous Close 0.424
Day's Range 0.401 - 0.401
52-Week Range 0.250 - 0.617
Beta n/a
RSI 38.95
Earnings Date Nov 25, 2025

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ... [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 40
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol P0F
Full Company Profile

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.